Cargando…

Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation

Cytokine-induced killer (CIK) cells are advanced therapy medicinal products, so their production and freezing process has to be validated before their clinical use, to verify their stability as a drug formulation according to the good manufacturing practice (GMP) guidelines. We designed a stability...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mareschi, Katia, Adamini, Aloe, Castiglia, Sara, Rustichelli, Deborah, Castello, Laura, Mandese, Alessandra, Leone, Marco, Pinnetta, Giuseppe, Mesiano, Giulia, Ferrero, Ivana, Fagioli, Franca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281026/ https://www.ncbi.nlm.nih.gov/pubmed/32408620 http://dx.doi.org/10.3390/ph13050093

Ejemplares similares

Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity
por: Sara, Castiglia, et al.
Publicado: (2018)

Correction to: Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identity
por: Castiglia, Sara, et al.
Publicado: (2018)

Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions
por: Mareschi, Katia, et al.
Publicado: (2020)

Evaluating Ecological Impact and Sustainability in the Manufacturing of Advanced Therapies: Comparative Analysis of Greenhouse Gas Emissions in the Production of ATMPs in Open and Closed Systems
por: Pinnetta, Giuseppe, et al.
Publicado: (2023)

Validation of analytical methods in GMP: the disposable Fast Read 102® device, an alternative practical approach for cell counting
por: Gunetti, Monica, et al.
Publicado: (2012)

A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions
por: Mareschi, Katia, et al.
Publicado: (2022)

Validation of analytical methods in compliance with good manufacturing practice: a practical approach
por: Rustichelli, Deborah, et al.
Publicado: (2013)

A Novel Xeno-Free Method to Isolate Human Endometrial Mesenchymal Stromal Cells (E-MSCs) in Good Manufacturing Practice (GMP) Conditions
por: Canosa, Stefano, et al.
Publicado: (2022)

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions
por: Castiglia, Sara, et al.
Publicado: (2014)

Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density: A More Advantageous Method for Clinical Use
por: Mareschi, Katia, et al.
Publicado: (2012)

Myogenic Potential of Whole Bone Marrow Mesenchymal Stem Cells In Vitro and In Vivo for Usage in Urinary Incontinence
por: Gunetti, Monica, et al.
Publicado: (2012)

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells
por: Bremm, Melanie, et al.
Publicado: (2019)

Organotypic spinal cord cultures: An in vitro 3D model to preliminary screen treatments for spinal muscular atrophy
por: Boido, Marina, et al.
Publicado: (2021)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions Preserves the Chemical Characteristics and Biological Activity of Lyo-Secretome Isolated by Ultrafiltration
por: Mareschi, Katia, et al.
Publicado: (2022)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
por: Ma, Yue, et al.
Publicado: (2012)

Precision Medicine in Osteosarcoma: MATCH Trial and Beyond
por: Tirtei, Elisa, et al.
Publicado: (2021)

Effect of In Vitro Exposure of Corticosteroid Drugs, Conventionally Used in AMD Treatment, on Mesenchymal Stem Cells
por: Nuzzi, Raffaele, et al.
Publicado: (2012)

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
por: Leuci, V., et al.
Publicado: (2018)

Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis
por: Hu, Jianxin, et al.
Publicado: (2017)

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukocyte antigen barriers
por: Circosta, Paola, et al.
Publicado: (2022)

Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
por: Bonanno, Giuseppina, et al.
Publicado: (2010)

In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy
por: Bremm, Melanie, et al.
Publicado: (2016)

Adjuvant Chemotherapy With Sequential Cytokine-Induced Killer (CIK) Cells in Stage IB Non-Small Cell Lung Cancer
por: Li, Da-Peng, et al.
Publicado: (2015)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

The role of cGMP as a mediator of lipolysis in bovine oocytes and its effects on embryo development and cryopreservation
por: Schwarz, Kátia R. L., et al.
Publicado: (2018)

A New Paclitaxel Formulation Based on Secretome Isolated from Mesenchymal Stem Cells Shows a Significant Cytotoxic Effect on Osteosarcoma Cell Lines
por: Banche Niclot, Alessia Giovanna Santa, et al.
Publicado: (2023)

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST
por: Fiorino, Erika, et al.
Publicado: (2022)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Correction: The role of cGMP as a mediator of lipolysis in bovine oocytes and its effects on embryo development and cryopreservation
por: Schwarz, Kátia R. L., et al.
Publicado: (2018)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

CD300LG improves the cytotoxic activity of CIK
por: Wang, Qiuyue, et al.
Publicado: (2017)

Inter-laboratory method validation of CD34+ flow-cytometry assay: the experience of Turin Metropolitan Transplant Centre
por: Ivana Ferrero, I.F., et al.
Publicado: (2023)

Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells
por: Zúñiga, Tiffany M., et al.
Publicado: (2022)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

Killers on Patrol: Liver Lymphocytes Remain in the Blood Vessels
Publicado: (2005)

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors
por: Wang, Ying, et al.
Publicado: (2015)

Genetic and Epigenetic Characterization of a Discordant KMT2A/AFF1-Rearranged Infant Monozygotic Twin Pair
por: Russo, Alessia, et al.
Publicado: (2021)

CIK细胞及其在肺癌治疗中的研究进展
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_blq2plq9j6av8dkakl80rq6n4e